Lo.Li. Pharma International has announced a new strategic partnering plan for its new product, Deplesin, which meets an unmet need for bipolar disorder (BD) patients. The discussions are underway with the aim of increasing accessibility to this novel adjunctive agent in the treatment of BD patients, who often experience a number of unpleasant and long-term side effects […]
